Compare CADL & JGH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CADL | JGH |
|---|---|---|
| Founded | 1999 | 2014 |
| Country | United States | United States |
| Employees | 55 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 357.4M | 285.5M |
| IPO Year | 2021 | N/A |
| Metric | CADL | JGH |
|---|---|---|
| Price | $4.79 | $11.91 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 7 | 0 |
| Target Price | ★ $19.71 | N/A |
| AVG Volume (30 Days) | ★ 1.2M | 89.0K |
| Earning Date | 03-12-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 9.85% |
| EPS Growth | ★ 58.62 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $125,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.25 | $10.51 |
| 52 Week High | $7.24 | $13.70 |
| Indicator | CADL | JGH |
|---|---|---|
| Relative Strength Index (RSI) | 42.63 | 25.35 |
| Support Level | $4.58 | N/A |
| Resistance Level | $5.42 | $12.92 |
| Average True Range (ATR) | 0.24 | 0.16 |
| MACD | 0.01 | -0.04 |
| Stochastic Oscillator | 28.15 | 5.26 |
Candel Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing off-the-shelf viral immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. The immune cells induced by these viral immunotherapies are believed to target patients' specific tumor antigens, potentially improving responses in immunologically hot tumors while at the same time infiltrating the tumor microenvironment, transforming non-inflamed cold tumors with limited immune response into hot tumors. The company has established two clinical off-the-shelf viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.
Nuveen Global High Income Fund operates as a diversified closed-end management investment company. Its investment objective is to provide a high level of current income. The Fund's securities include U.S. high-yield bonds; non-U.S. high-yield bonds from developed and emerging markets; and other income-producing investments such as preferred and convertible securities.